170 related articles for article (PubMed ID: 28946040)
1. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.
Tella SH; Taïeb D; Pacak K
Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040
[TBL] [Abstract][Full Text] [Related]
2. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
3. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E
Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286
[TBL] [Abstract][Full Text] [Related]
4. 3-[(1
Xu R; Wang K; Rizzi JP; Huang H; Grina JA; Schlachter ST; Wang B; Wehn PM; Yang H; Dixon DD; Czerwinski RM; Du X; Ged EL; Han G; Tan H; Wong T; Xie S; Josey JA; Wallace EM
J Med Chem; 2019 Aug; 62(15):6876-6893. PubMed ID: 31282155
[TBL] [Abstract][Full Text] [Related]
5. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma.
Yu Y; Yu Q; Zhang X
Drug Discov Today; 2019 Dec; 24(12):2332-2340. PubMed ID: 31541711
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster.
Fliedner SM; Shankavaram U; Marzouca G; Elkahloun A; Jochmanova I; Daerr R; Linehan WM; Timmers H; Tischler AS; Papaspyrou K; Brieger J; de Krijger R; Breza J; Eisenhofer G; Zhuang Z; Lehnert H; Pacak K
Neoplasia; 2016 Sep; 18(9):567-76. PubMed ID: 27659016
[TBL] [Abstract][Full Text] [Related]
8. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
Gong K; Zhang N; Zhang K; Na Y
Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
[TBL] [Abstract][Full Text] [Related]
9. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.
Cho H; Du X; Rizzi JP; Liberzon E; Chakraborty AA; Gao W; Carvo I; Signoretti S; Bruick RK; Josey JA; Wallace EM; Kaelin WG
Nature; 2016 Nov; 539(7627):107-111. PubMed ID: 27595393
[TBL] [Abstract][Full Text] [Related]
10. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
11. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
[TBL] [Abstract][Full Text] [Related]
12. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
Wehn PM; Rizzi JP; Dixon DD; Grina JA; Schlachter ST; Wang B; Xu R; Yang H; Du X; Han G; Wang K; Cao Z; Cheng T; Czerwinski RM; Goggin BS; Huang H; Halfmann MM; Maddie MA; Morton EL; Olive SR; Tan H; Xie S; Wong T; Josey JA; Wallace EM
J Med Chem; 2018 Nov; 61(21):9691-9721. PubMed ID: 30289716
[TBL] [Abstract][Full Text] [Related]
13. HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice.
Hoefflin R; Harlander S; Schäfer S; Metzger P; Kuo F; Schönenberger D; Adlesic M; Peighambari A; Seidel P; Chen CY; Consenza-Contreras M; Jud A; Lahrmann B; Grabe N; Heide D; Uhl FM; Chan TA; Duyster J; Zeiser R; Schell C; Heikenwalder M; Schilling O; Hakimi AA; Boerries M; Frew IJ
Nat Commun; 2020 Aug; 11(1):4111. PubMed ID: 32807776
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma.
Sandlund J; Ljungberg B; Wikström P; Grankvist K; Lindh G; Rasmuson T
Acta Oncol; 2009; 48(6):909-14. PubMed ID: 19322701
[TBL] [Abstract][Full Text] [Related]
15. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Courtney KD; Infante JR; Lam ET; Figlin RA; Rini BI; Brugarolas J; Zojwalla NJ; Lowe AM; Wang K; Wallace EM; Josey JA; Choueiri TK
J Clin Oncol; 2018 Mar; 36(9):867-874. PubMed ID: 29257710
[TBL] [Abstract][Full Text] [Related]
16. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Courtney KD; Ma Y; Diaz de Leon A; Christie A; Xie Z; Woolford L; Singla N; Joyce A; Hill H; Madhuranthakam AJ; Yuan Q; Xi Y; Zhang Y; Chang J; Fatunde O; Arriaga Y; Frankel AE; Kalva S; Zhang S; McKenzie T; Reig Torras O; Figlin RA; Rini BI; McKay RM; Kapur P; Wang T; Pedrosa I; Brugarolas J
Clin Cancer Res; 2020 Feb; 26(4):793-803. PubMed ID: 31727677
[TBL] [Abstract][Full Text] [Related]
17. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
Jochmanová I; Yang C; Zhuang Z; Pacak K
J Natl Cancer Inst; 2013 Sep; 105(17):1270-83. PubMed ID: 23940289
[TBL] [Abstract][Full Text] [Related]
19. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1α/miR-210 signaling pathway.
Merlo A; de Quirós SB; de Santa-María IS; Pitiot AS; Balbín M; Astudillo A; Scola B; Arístegui M; Quer M; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1661-6. PubMed ID: 23902947
[TBL] [Abstract][Full Text] [Related]
20. A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2α as the major player in its pathogenesis and future therapeutic options.
Jochmanova I; Lazurova I
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):175-80. PubMed ID: 24781045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
